Merck’s Molnupiravir paper in NEJM contains fabricated data

Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.by Leo Goldstein

Merck’s newest Molnupiravir study (Bernal et al., NEJM), published in NEJM, ​​contains fabricated data about coronavirus clearance (Appendix, Table S6). The rates of virus clearance from day 10 to 29 are too similar between the Molnupiravir and Placebo arms. The differences are too small compared with the large standard deviations. The standard deviations are too similar, too. This data manipulation shows that the virus clearance in the Molnupiravir arm was slower than in the placebo arm.

This is consistent with the analysis of earlier Merck’s Molnupiravir studies. Patients who started Molnupiravir earlier had worse outcomes than those who started treatment later - exactly the opposite of what one expects from an antiviral treatment. Part 2 of Phase 3 MOVe-OUT trial shows overall worse outcomes for Molnupiravir patients. Part 1 of that trial has serious integrity issues, and the placebo group’s death rates are much higher than ever found in similar population.

Earlier Molnupiravir studies that were reported to AMDAC had more shocking re...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee